Lexington Avenue

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Retrieved on: 
Thursday, March 7, 2024

The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.

Key Points: 
  • The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.
  • The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions.
  • In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 1,016,128 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel are acting as joint book-running managers for the offering.

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Retrieved on: 
Tuesday, March 5, 2024

In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
  • Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen, and Stifel are acting as joint book-running managers for the proposed offering.
  • This offering will be made only by means of a written prospectus.

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

Retrieved on: 
Tuesday, March 5, 2024

Rodman & Renshaw LLC and StockBlock Securities LLC were the underwriters and acted as the joint book-running managers for the offering.

Key Points: 
  • Rodman & Renshaw LLC and StockBlock Securities LLC were the underwriters and acted as the joint book-running managers for the offering.
  • The Company has granted to the underwriters a 30-day option to purchase up to an additional 882,352 shares of common stock and/or Common Warrants at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds to the Company, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriters’ option to purchase additional shares of common stock and/or Common Warrants, were approximately $10 million.
  • The securities described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No.

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, March 5, 2024

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share.

Key Points: 
  • HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share.
  • All of the shares sold in the offering were sold by Celldex.
  • The gross proceeds to Celldex from this offering were approximately $460.5 million, excluding underwriting discounts and commissions and other offering-related expenses.
  • Leerink Partners, TD Cowen, Guggenheim Securities and Cantor acted as the joint bookrunning managers for the offering.

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Retrieved on: 
Monday, March 4, 2024

WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The total gross proceeds of the public offering were approximately $172.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis.
  • All of the shares in the public offering were sold by Arcutis.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities acted as joint lead bookrunning managers for the offering.

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, March 1, 2024

The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full.

Key Points: 
  • The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $86.4 million.
  • All of the shares in the offering were sold by Absci.
  • The shares of common stock were offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No.

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024

The aggregate gross proceeds from this offering are expected to be $40.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte.

Key Points: 
  • The aggregate gross proceeds from this offering are expected to be $40.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte.
  • The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions.
  • In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,010,000 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions.
  • All of the shares of common stock are being sold by Humacyte.

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024

HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.

Key Points: 
  • HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.
  • All of the shares to be sold in the offering are to be sold by Celldex.
  • In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters’ option, if any, of approximately $400.4 million, excluding underwriting discounts and commissions and other offering-related expenses.

Scilex Holding Company Announces $10 Million Bought Deal Offering

Retrieved on: 
Thursday, February 29, 2024

The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions.
  • Rodman & Renshaw LLC and StockBlock Securities LLC are acting as the joint book-running managers for the offering.
  • The Company also has granted to the underwriters a 30-day option to purchase up to an additional 882,352 shares of common stock and/or Common Warrants at the public offering price, less underwriting discounts and commissions.
  • The securities described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No.

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Thursday, February 29, 2024

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it has commenced an underwritten public offering of its common stock.

Key Points: 
  • DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it has commenced an underwritten public offering of its common stock.
  • In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering.
  • TD Cowen and Cantor are acting as joint book-running managers for the offering.
  • The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.